TWITTER SPACES & TWEETORIALS: A FOCUS ON DIABETES & CKD DISPARITIES 

EDAN, in partnership with Med-IQ, created type 2 diabetes (T2D)-related education for healthcare professionals who work with individuals diagnosed with T2D and chronic kidney disease (CKD). This series is available on Twitter in the form of two Tweetorials and one Twitter Spaces discussion. These programs combine the expertise of various specialists and present their management approaches for two individuals with T2D and CKD within the context of newly released clinical practice guidelines. 

Meet 2 patients – Celia and Kevin. Our team of expert faculty discussed their management approaches for these two individuals with type 2 diabetes and chronic kidney disease within the context of newly released clinical practice guidelines. Listen to their thoughts.

You can see Celia’s and Kevin’s cases on Twitter to follow along.

This activity was supported by an educational grant from Coverys Community Healthcare Foundation, Inc.

Addressing Diabetes Disparities with Project ECHO®: A Focus on Diabetes-Related CKD

Inequities are endemic to the US healthcare system and significantly affect our patients living with diabetes. It’s time for change.

We understand the important role primary care professionals (PCPs) play in the lives of individuals with diabetes, particularly in underserved communities. Many people who require complex diabetes management typically receive care from PCPs rather than from diabetes specialists. This initiative addresses the urgent and persistent needs of vulnerable populations of people with diabetes, targeting those who also have CKD. Through this series, we seek to empower PCPs and to increase their capacity to screen, diagnose, and manage renal complications of diabetes using the Project ECHO (Extension for Community Healthcare Outcomes) model.

Each of the 4 sessions focused on the “ABCDES” needed to improve diabetes care: Access, Beyond A1C, Confidence, Disparities, Education, and Systems. Our hub team of experts is a diverse group of thought leaders from 8 academic institutions across the US and a diabetes advocacy organization who provided foundational education, case-based mentoring in real time, and a holistic perspective of every opportunity and barrier discussed. 

Thank you for being a champion for people with diabetes!

This activity was supported by an educational grant from Bayer HealthCare Pharmaceuticals.

SESSIONS

  • Approaches to Identifying CKD & the New Kidney Health Evaluation

    Katherine R. Tuttle, MD, FASN, FACP, FNKF

    At the end of this session, participants should be able to:

    • Describe the new 2-test HEDIS® Kidney Health Evaluation for Patients With Diabetes (KED) screening and the need for the measure

    • Increase evidence-based screening in underserved populations to address disparities in care and prevent diabetes complications

    • Prepare to improve patient care by using the new HEDIS® Kidney Health Evaluation for Patients With Diabetes (KED) measure to address gaps in screening

    Downloads:
    >     Handouts
    > Case Recommendations

  • Looking Beyond Glucose Control: Best Practices to Address Diabetes-Related CKD

    Robert Gabbay, MD, PhD, FACP

    At the end of this session, participants should be able to:

    • Use the American Diabetes Association’s guidelines to identify evidence-based treatment for patients with type 2 diabetes regardless of HbA1C level

    • Identify appropriate pharmacotherapy for patients with type 2 diabetes based on indicators for those who are at high risk of or who have atherosclerotic cardiovascular disease, CKD, or heart failure

    • Prepare to use SGLT2 inhibitors to reduce CKD progression in patients with type 2 diabetes, independent of glycemic control

    Downloads:
    > Handouts
    > Case Recommendations

  • Addressing CKD Disparities and Social Determinants of Health to Achieve Diabetes Management Goals

    Crystal Gadegbeku, MD, FASN
    George Thomas, MD

    At the end of this session, participants should be able to:

    • Identify the disproportionate prevalence of CKD in different racial and ethnic populations

    • Assess how racial, gender, and socioeconomic factors affect patient access to evidence-based treatment options

    • Strategize ways to address biases that may lead to prescribing disparities in your practice

    • Optimize hypertension and CKD prevention/management in your patients with type 2 diabetes

    Downloads:
    > Handouts
    > Case Recommendations

  • Halting CKD Progression: From Optimizing Hypertension Management to Newer Agents

    Joseph Vassalotti, MD

    At the end of this session, participants should be able to:

    • Enhance hypertension detection and management in your patients with type 2 diabetes

    • Describe the role of SGLT2 inhibitors in minimizing CKD progression in patients with type 2 diabetes

    • Use the latest clinical evidence regarding the use of nonsteroidal mineralocorticoid receptor antagonists for treating patients with hypertension and type 2 diabetes

    Downloads:
    > Handouts
    > Case Recommendations

Hub Faculty

Nayan Arora, MD - Hub Faculty
Nephrologist

Clinical Assistant Professor, Medicine, Division of Nephrology, University of Washington, Seattle, WA

 

Matthew Bouchonville, MD, CDCES - Hub Faculty
Endocrinologist

Associate Professor, Department of Medicine, University of New Mexico, School of Medicine, Medical Director UNM Diabetes Comprehensive Care Center, UNM Center for Diabetes and Nutrition Education, Albuquerque, NM

 

Kelly Close, MBA - Hub Faculty
Patient Advocate

Founder, diaTribe Foundation, San Francisco, CA

 

Nicolas Cuttriss, MD, MPH, FAAP - Hub Faculty
Pediatric Endocrinologist

Founding Director & CEO, ECHO Diabetes Action Network, Washington, DC

 

Phyllisa Deroze, PhD - Hub Faculty
Patient Advocate

Director of Research, The Diabetes Research Company, Pompano Beach, FL

 

Korey Hood, PhD - Hub Faculty
Psychologist

Professor of Pediatrics, Psychiatry and Behavioral Sciences, Staff Psychologist, Stanford University School of Medicine, Palo Alto, CA

 

Sean Oser, MD, MPH - Hub Faculty
Primary Care Physician

Associate Professor, Family Medicine, University of Colorado School of Medicine, Denver, CO

 

Daniel Saltman, MD, FACP - Hub Faculty
Internal Medicine Physician

Associate Clinical Professor, Department of Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI

 

Jay H. Shubrook, DO - Hub Faculty
Primary Care Physician

Professor, Touro University California, Vacaville, CA

 

Lisa Taylor, DNP, FNP-BC, BC-ADM, CDCES - Hub Faculty
Nurse Practitioner

Assistant Clinical Professor, University of New Mexico, Albuquerque, NM

 

Julie Valdes, PharmD, CDCES, CTTS - Hub Faculty
Pharmacist

Zufall Health Center, Dover, NJ

 

Presenting Faculty

Robert Gabbay, MD, PhD, FACP - Presenting Faculty
Endocrinologist

Chief Science & Medical Officer, American Diabetes Association, Arlington, VA

 

Crystal Gadegbeku, MD, FASN - Presenting Faculty
Nephrologist

Chair of Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, American Society of Nephrology Councilor

 

George Thomas, MD - Presenting Faculty
Nephrologist

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

 

Katherine R. Tuttle, MD, FASN, FACP, FNKF - Presenting Faculty
Nephrologist & Endocrinologist

Executive Director for Research, Providence Health Care, Professor of Medicine, Division of Nephrology Co-Principal Investigator, Institute of Translational Health Sciences, Spokane, WA

 

Joseph Vassalotti, MD - Presenting Faculty
Nephrologist

Clinical Professor of Medicine, Icahn School of Medicine at Mount Sinai, Chief Medical Officer, National Kidney Foundation, New York, NY